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Abstract
Low phospholipid-associated cholelithiasis (LPAC) is characterized by the association of ABCB4
mutations and low biliary phospholipid concentration with symptomatic and recurring
cholelithiasis. This syndrome is infrequent and corresponds to a peculiar small subgroup of patients
with symptomatic gallstone disease. The patients with the LPAC syndrome present typically with
the following main features: age less than 40 years at onset of symptoms, recurrence of biliary
symptoms after cholecystectomy, intrahepatic hyperechoic foci or sludge or microlithiasis along
the biliary tree. Defect in ABCB4 function causes the production of bile with low phospholipid
content, increased lithogenicity and high detergent properties leading to bile duct luminal
membrane injuries and resulting in cholestasis with increased serum gamma-glutamyltransferase
(GGT) activity. Intrahepatic gallstones may be evidenced by ultrasonography (US), computing
tomography (CT) abdominal scan or magnetic resonance cholangiopancreatography, intrahepatic
hyperechogenic foci along the biliary tree may be evidenced by US, and hepatic bile composition
(phospholipids) may be determined by duodenoscopy. In all cases where the ABCB4 genotyping
confirms the diagnosis of LPAC syndrome in young adults, long-term curative or prophylactic
therapy with ursodeoxycholic acid (UDCA) should be initiated early to prevent the occurrence or
recurrence of the syndrome and its complications. Cholecystectomy is indicated in the case of
symptomatic gallstones. Biliary drainage or partial hepatectomy may be indicated in the case of
symptomatic intrahepatic bile duct dilatations filled with gallstones. Patients with end-stage liver
disease may be candidates for liver transplantation.
Disease name and synonyms
Low phospholipid associated cholelithiasis
Cholelithiasis with ABCB4 gene mutation
ABCB4 gene mutation-associated cholelithiasis
Definition
Low phospholipid-associated cholelithiasis (LPAC) is
characterized by the association of ABCB4 mutations with
symptomatic and recurring cholelithiasis in young adults
(e.g. <40 years).
Epidemiology
The exact prevalence of LPAC remains unknown. The dis-
ease is more common in young adults, the usual age at the
onset of the symptoms is typically lower than 40 years.
The male to female ratio is estimated at approximately
1:3. However, at present, the literature data and our
results did not allow to determine the frequency of ABCB4
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mutations in the whole population of patients with chole-
lithiasis.
Up to 10% of the European and American population
carry gallstones, approximately 25% of cases have symp-
toms and less than 2% present with severe complications
(cholangitis or pancreatitis). Based on previous epidemi-
ological data, we consider that LPAC syndrome is infre-
quent and corresponds to a peculiar subgroup of patients
with symptomatic gallstone disease [1,2]. Considering the
advances in molecular diagnosis of the disease, the undi-
agnosed cases could be identified and provide data about
the prevalence of LPAC.
Clinical description
LPAC presents as a peculiar form of cholelithiasis charac-
terized by cholecystitis, cholangitis and intrahepatic gall-
stone disease, and/or acute pancreatitis associated with
biliary microlithiasis. Most patients report a history of
cholesterol gallstones amongst their first-degree relatives.
Intrahepatic hyperechoic foci are characteristic sign of the
LPAC syndrome. Intrahepatic gallstones or sludge and
increased serum gamma-glutamyl transferase (GGT)
activity are frequently present. It suggests that the biliary
symptoms experienced by these patients are probably
caused by cholesterol crystal deposits and bile duct
inflammation but not directly and exclusively related to
the presence of detectable gallstones. Increased choles-
terol saturation index and a defect in the hepatic transport
and biliary secretion of phospholipids in patients with an
intrahepatic cholesterol gallstone disease or an acute pan-
creatitis associated with biliary microlithiasis have been
shown in another studies [3,4].
The typical biliary pain in patients with LPAC syndrome
(associated with detectable gallstones or not) often leads
to decision of cholecystectomy. The majority of patients is
our series (90%) underwent cholecystectomy but recur-
rence of the symptoms was observed in half of them,
despite cholecystectomy [5]. The onset of symptoms typi-
cal for LPAC syndrome have been reported at the end of
or following pregnancy (56% of women with early onset
of symptoms and ABCB4 mutations presented also with
an history of intrahepatic cholestasis of pregnancy and
14% had fetal complications) [6]. Prophylactic therapeu-
tic activity of ursodeoxycholic acid (UDCA) has been
demonstrated in the majority of patients [5]. Of note, the
benefit of UDCA therapy on the resolution of biliary
symptoms occurred long before the dissolution of the int-
rahepatic stones. Therefore, recurrence despite cholecys-
tectomy, association with intrahepatic cholestasis of
pregnancy and prevention by UDCA represent major clin-
ical features that support the diagnosis of LPAC syn-
drome.
Etiology
Phospholipids are the major carrier and solvent of choles-
terol and they exert a protective effect against bile salt-
induced biliary mucosa injury. Homozygous and hetero-
zygous mutations in the MDR3  (now referred to as
ABCB4) gene, the phosphatidylcholine translocator
across the canalicular membrane, are thought to be
responsible for progressive intrahepatic cholestasis type 3
(PFIC 3) [7], and heterozygous mutations have been also
reported in patients presenting with a history of intrahe-
patic cholestasis of pregnancy or with a cholangiopathy
referred to as anti-mitochondrial antibody (AMA) nega-
tive primary biliary cirrhosis (PBC) [8-11]. Defect in
ABCB4 function causes the production of bile with low
phospholipid content, increased lithogenicity and high
detergent properties leading to bile duct luminal mem-
brane injuries and resulting in cholestasis with increased
serum GGT activity.
We determined more generally the frequency of ABCB4
gene mutations in 60 consecutive adult patients who had
been referred to our liver unit because of symptomatic or
complicated cholelithiasis and we characterized more pre-
cisely the clinical phenotype associated with these muta-
tions [12]. Among these patients, 32 were referred
specifically for ABCB4 gene analysis because of clinical
history compatible with the syndrome that we previously
described (i.e. presenting at least 3 of the following clini-
cal criteria: age at the onset of symptoms lower than 40
years; association with cholecystitis, cholangitis or acute
pancreatitis; recurrence of symptoms despite cholecystec-
tomy; intrahepatic hyperechoic foci (Figure 1) with or
without intrahepatic sludge or microlithiasis). Twenty-
eight of these patients were referred after a cholecystec-
tomy for a symptomatic gallstone disease and 33 other
consecutive patients were referred for diverse acute or
chronic liver diseases without biliary gallstones (chronic
HBV or HCV hepatitis, non-alcoholic steatohepatitis,
drug-induced hepatitis or a classic genetic hemochroma-
tosis).
Clinical phenotype associated with ABCB4 gene 
mutations
Among the 32 patients suspected of having the syndrome,
18 (56%, CI 95% [52%–62%]) presented a point muta-
tion at the ABCB4 locus, while none of the 28 patients
with a classical form of cholelithiasis and none of the 33
patients without cholelithiasis had mutation in the
ABCB4 gene (p < 0,001 and p < 0,0001; respectively).
Multivariate analysis showed that among patients with
cholelithiasis three independent factors were predictive of
a mutation at the ABCB4 locus: a recurrence of symptoms
after cholecystectomy (adjusted OR = 8.5), intrahepatic
hyperchoic material (adjusted OR = 6.1), and age <40
years (adjusted OR = 3.0) [9].Orphanet Journal of Rare Diseases 2007, 2:29 http://www.OJRD.com/content/2/1/29
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Finally, more recent data shows that the LPAC syndrome
is more frequent in females and that biliary symptoms
occur earlier in female who present a nonsense mutation
[6].
Characterization of the ABCB4 gene mutations in 
patients with the LPAC syndrome
Patients were screened for mutations in the ABCB4 gene
using polymerase chain reaction (PCR) amplification and
DNA sequencing of exons 2 to 28 and all splice junctions.
We identified 14 heterozygous and homozygous point
mutations amongst these 18 patients. None of these
mutations was detected in a control panel of 140 chromo-
somes demonstrating that they did not correspond to pol-
ymorphisms (SNPs). Affected patients with heterozygous
mutations exhibited 1bp-insertion, 1bp-deletion, non-
sense mutations or missense mutations resulting in a
frameshift predicted to cause premature messenger RNA
termination, a loss of protein function and single-nucle-
otide substitutions, while affected patients with
homozygous mutations demonstrated only missense
mutations. Most mutations were localized in the central
part of the molecule, close to nucleotide binding domain
1 (NBD1), or in adjacent transmembrane domains and
intracellular loops (Figure 2). Eighty percent of mutations
were indeed situated in regions encoded by exons 9 to 18,
which corresponded approximately to 38% of the encod-
ing region (TM 5 and 6; 3rd intracellular loop including
NBD1; TM 7 and 8).
Possible disease-causing mutation
The definition of a disease-causing mutation (DCM) is
problematic when functional assays to determine the phe-
notypic effects of specific variants are not available or have
not been performed. To date, two of the missense muta-
tions (Glu528Asp and Thr175Ala) detected in patients
with the LPAC syndrome had been analyzed previously in
a homolog of ABCB4 (Pgp now called ABCB1) in yeast
[13,14]. The Thr175Ala mutation was localized in the 1st
intracellular loop and resulted in a substitution in a con-
served cluster of four amino-acids at position 169–172,
required for the adenosine triphosphatase activity of the
molecule. This mutant resulted in a complete loss of drug-
induced P-gp ATPase activity. The Phe165Ile mutation
was localized in the same part of this intracellular loop
and may therefore give rise to a similar defect. The
Glu528Asp mutation was localized close to the NBD1.
The glutamic acid is included in a small amino-acid clus-
ter localized before the walker B motif which is required
for drug-induced ATPase activity. These mutations indeed
induced a loss of function of the molecule in vitro. It
should be noted that the two unrelated patients in whom
the Thr175Ala mutation was identified originated from
Northern Europe, so they may have inherited a founder
mutation from a shared ancestor. This mutation has also
been recently identified in adults with cholangiopathy
and intrahepatic cholestasis of pregnancy [11]. The muta-
tion S320F has also been recently identified in a patient
with intrahepatic cholestasis of pregnancy and cholelithi-
asis [7,11].
Only  ABCB4  sequence alterations leading to predicted
premature truncation of the protein, small deletions or
insertions and non-conserved missense mutations were
considered as potential DCMs. Even if this restriction was
taken into account, a certain number of arguments
Localization of the DCMs in the different domains of the  ABCB4 protein in the complete series of patients with LPAC Figure 2
Localization of the DCMs in the different domains of the 
ABCB4 protein in the complete series of patients with LPAC.
Ultrasound images of intrahepatic hyperechoic foci in  patients with the LPAC syndrome Figure 1
Ultrasound images of intrahepatic hyperechoic foci in 
patients with the LPAC syndrome. In these patients, a careful 
US examination detected intrahepatic hyperechoic foci with 
diffuse topography compatible with lipid deposits along the 
luminal surface of the intrahepatic biliary tree (Arrows). 
These multiple dots, less than 1 mm in diameter, cast short 
echogenic trail without acoustic shadows and looked like 
comet tails. They were typically distributed along the portal 
arborizations and may be associated with intrahepatic sludge 
or microlithiasis casting typical acoustic shadows.Orphanet Journal of Rare Diseases 2007, 2:29 http://www.OJRD.com/content/2/1/29
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strongly supported a pathogenic role for ABCB4  gene
mutations. These mutations are indeed detected at high
frequency in patients with LPAC syndrome; they affect
only highly conserved amino acids between human and
rodent homologues of the gene and no mutation was
detected in an independent control panel of 140 chromo-
somes. In addition, LPAC syndrome was observed in
patients exhibiting the same or similar nonsense or mis-
sense mutations: in a mother and her elder son with an
identical heterozygous nonsense mutation (1327insA); in
independent patients from non-consanguineous families
with the same homozygous missense mutation
(Ser320Phe or Ala934Thr), while their heterozygous par-
ents were asymptomatic; in patients with a similar non-
sense mutation (1006-1016insT and 1006-1016delT) and
in unrelated patients with the same missense mutations
(Pro1161Ser). For all these reasons, these mutations
could be considered as causing the LPAC syndrome.
These results and data in the literature therefore strongly
suggest that ABCB4  mutations may lead to cholesterol
cholelithiasis when residual ABCB4  activity and subse-
quent biliary phospholipid secretion fall below a critical
threshold which may depend on the type of mutation and
on other host or environmental factors, including proba-
bly bacterial infection of the bile ducts (Carey et al. Per-
sonnal Communication. Falk Symposium 2004).
Alternative molecular mechanisms of LPAC syndrome
The mutation screening method used in our two studies
was unable to detect major DNA rearrangements, and nor
did the analysis include the promoter or other potential
regulation regions of the gene. As 44% of LPAC patients
did not present ABCB4 gene point mutation, defects in the
promoter region or large DNA rearrangements might also
be involved in some patients presenting with LPAC syn-
drome. Alternatively, defects in other regions of the gene
or in other genes may also be involved, and some evi-
dence from animal studies has pointed to Abcb 11 (previ-
ously called the bile salt export pump, BSEP),  Abcc  2
(previously referred to as multidrug resistance related pro-
tein 2, or MRP2) or Abcg5/Abcg8 as other possible candi-
date genes underlying susceptibility to cholelithiasis [15-
19] or phospholipid secretion disruption [20].
Animal models of the LPAC syndrome
It has also been shown that substantial amounts of cho-
lesterol are secreted by Mdr2 (-/-) mice on a cholate-sup-
plemented diet and microscopic examination of the
gallbladder reveals massive amount of cholesterol crystals
and that after 12 weeks, 50% of the Mdr2 (-/-) mice on
chow also developed gallstones composed of needlike
"anhydrous" cholesterol crystals and mucin [21,22].
Indeed, although bile of these mice contain traces only of
cholesterol, they are supersaturated with cholesterol (CSI
≥ 1.05) and intrahepatic bile duct are filled with crystal-
line occlusions composed of needle-like crystals plus
mucin gel in 7-month-old mice. Female Mdr2 -/- mice dis-
play a more hydrophobic bile salt pool due to a lower
tauro-beta-muricholate level in bile and increasing bile
hydrophobicity has been demonstrated in vitro to enhance
cholesterol crystallization. This mechanism explains the
early and higher prevalence of gallstones in female Mdr2
-/- mice and provide a rationale for substitution of more
hydrophobic bile salts with ursodeoxycholic acid in LPAC
patients [21].
ABCB4 gene mutations and primary sclerosing cholangitis
As a recent study reported that Mdr2 KO mice develop
liver lesions mimicking sclerosing cholangitis character-
ized by biliary strictures and dilatations [23], we also
looked for ABCB4 gene mutations and sequence diversity
in 34 consecutive patients with primary sclerosing cholan-
gitis. We found no ABCB4 gene mutations and no abnor-
mal SNP frequency in these unselected PSC patients [24].
These data are consistent with the results of the recent
study of the group from Zurich which observed no signif-
icant deviation in haplotype structure in ABCB4 from that
observed in healthy Caucasian controls [25]. Thus, these
results, unlike the bile duct lesions observed in mice, do
not support a major role of ABCB4 genetic variation in the
pathogenesis of the PSC, although an implication of
ABCB4  cannot be ruled out in a subgroup of these
patients.
Cholelithiasis and ABCB4 gene mutation-associated liver 
diseases in adults
Cholesterol cholelithiasis was also demonstrated in
patients with progressive familial intrahepatic cholestasis-
3 (PFIC3) and some of their relatives [7,26], and in
patients with a clinical presentation of intrahepatic
cholestasis of pregnancy [27-30]. In addition, a multidrug
resistance 3 gene mutation in exon 14 has been recently
detected in a patient who developed cholelithiasis in ado-
lescence, followed by cholestasis of pregnancy and finally
adulthood biliary cirrhosis [31]. Finally, we also observed
in some patients presenting with the LPAC syndrome the
presence of localized or diffuse intrahepatic non cystic
bile duct dilatations filled with cholesterol gallstones (Fig-
ure 3). These peculiar bile duct dilatations as well as some
cases of adulthood biliary cirrhosis may therefore be con-
sidered as severe complications of the LPAC syndrome.
Diagnosis and diagnostic methods
In patients with symptomatic cholelithiasis, the presence
of additional hepatobiliary manifestations (age at onset of
biliary symptoms, intermittent cholestatic attachs, mate-
rial or sludge in the intrahepatic bile ducts, recurrence of
biliary symptoms after cholecystectomy etc.) should
remind of this rare monogenic form of cholelithiasis (e.g.
LPAC syndrome) for which genetic testing may be offered
by several genetic laboratories.Orphanet Journal of Rare Diseases 2007, 2:29 http://www.OJRD.com/content/2/1/29
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Diagnostic criteria
The LPAC syndrome should be supposed in cases with
clinical history of symptomatic cholelithiasis with at least
one of the following criteria: age less than 40 years at
onset of symptoms, recurrence after cholecystectomy, int-
rahepatic hyperechoic foci with a topography compatible
with lipid deposits along the luminal surface of the intra-
hepatic biliary tree, intrahepatic sludge, microlithiasis,
familial history of cholelithiasis in first-degree relatives, or
clinical history of intrahepatic intrahepatic cholestasis of
pregnancy.
Diagnostic methods
• Intrahepatic gallstones evidenced by ultrasonography
(US), computing tomography (CT) abdominal scan or
magnetic resonance cholangiopancreatography;
• Intrahepatic hyperechogenic foci along the biliary tree
by US;
• Hepatic bile composition (obtained by duodenoscopy
and aspiration using a catheter introduced in the distal
common bile duct or by T-tube after surgery);
• ABCB4 gene analysis.
Differential diagnosis
Other inflammatory bile duct diseases which may lead to
biliary symptoms and/or intrahepatic gallstones (includ-
ing Caroli disease, primary scherosing cholangitis).
Genetic counseling
ABCB4 genotyping should be used to confirm the diagno-
sis of LPAC syndrome in young adults who present with a




Special diet is not required. In all cases where the ABCB4
genotyping confirms the diagnosis of LPAC syndrome in
young adults, long-term curative or prophylactic therapy
with UDCA should be initiated early to prevent the occur-
rence or recurrence of the syndrome and its complica-
tions. UDCA was shown to up-regulate the expression of
the protein at the canalicular membrane, minimize the
toxicity of the endogenous hydrophobic bile acids and
increase the pool of protective hydrophilic bile acids.
In the case of associated hypercholesterolemia, statins
should be preferred to fibrates which increase the litho-
genicity of the bile.
Surgical treatment
Cholecystectomy is indicated in the case of symptomatic
gallstones but not when only sludge is present in the gall-
bladder.
Biliary drainage or partial hepatectomy may be indicated
in the case of symptomatic intrahepatic bile duct dilata-
tion filled with gallstones.
Patients with end-stage liver disease may be candidates for
liver transplantation.
Future pharmacological treatment
Drugs that may induce ABCB4 expression.
Clinical course and outcome
Typically, the clinical course is progressive, with multiple
recurrence despite the operative intervention(s) until
UDCA treatment is started.
The majority of patients with LPAC syndrome described
in the literature do not develop recurrence or end-stage
liver disease under medical treatment.
Conclusion
In summary, our results strongly support the role of an
ABCB4 gene defect in LPAC syndrome and replace it in the
context of ABCB4 gene-associated liver diseases in adults
including attenuated form of PFIC 3, "atypical intrahe-
patic cholestasis of pregnancy", LPAC syndrome which
might lead to adulthood biliary cirrhosis or bile duct dil-
atations associated with gallstones. A genetic test based on
the present results may permit the molecular diagnosis of
LPAC syndrome associated with the presence of intrahepatic  non cystic bile duct dilatations filled with cholesterol gall- stones Figure 3
LPAC syndrome associated with the presence of intrahepatic 
non cystic bile duct dilatations filled with cholesterol gall-
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LPAC syndrome and the screening of high-risk subjects.
Depending on the results, long-term curative or prophy-
lactic UDCA therapy may be initiated early to prevent the
occurrence or recurrence of this syndrome and its severe
complications.
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